NCT05971589View on ClinicalTrials.gov

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

August 31, 2026

Conditions
Solid Tumor
Interventions
BIOLOGICAL

LM103

Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.

All Listed Sponsors
lead

Suzhou BlueHorse Therapeutics Co., Ltd.

INDUSTRY

NCT05971589 - A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors | Biotech Hunter | Biotech Hunter